11/15
09:17 am
omga
Omega Therapeutics, Inc. (NASDAQ: OMGA) was downgraded by analysts at Raymond James from an "outperform" rating to a "market perform" rating.
High
Report
Omega Therapeutics, Inc. (NASDAQ: OMGA) was downgraded by analysts at Raymond James from an "outperform" rating to a "market perform" rating.
11/15
08:02 am
omga
Omega Therapeutics, Inc. (NASDAQ: OMGA) had its price target lowered by analysts at Piper Sandler from $9.00 to $4.00. They now have an "overweight" rating on the stock.
High
Report
Omega Therapeutics, Inc. (NASDAQ: OMGA) had its price target lowered by analysts at Piper Sandler from $9.00 to $4.00. They now have an "overweight" rating on the stock.
11/14
04:05 pm
omga
Omega Therapeutics Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller, Prioritized Pipeline, Leadership Changes, and Third Quarter 2024 Financial Results
High
Report
Omega Therapeutics Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller, Prioritized Pipeline, Leadership Changes, and Third Quarter 2024 Financial Results
10/15
08:00 am
omga
Omega Therapeutics to Present Multiple Posters Highlighting Versatile Platform Capabilities at Upcoming Scientific Meetings
Medium
Report
Omega Therapeutics to Present Multiple Posters Highlighting Versatile Platform Capabilities at Upcoming Scientific Meetings
9/17
07:00 am
omga
Omega Therapeutics Announces Publication of Epigenomic Controller OTX-2002 Preclinical Data in Nature Communications
Low
Report
Omega Therapeutics Announces Publication of Epigenomic Controller OTX-2002 Preclinical Data in Nature Communications